From GlobeNewswire: 2024-07-28 16:51:00

Longeveron Inc. presented positive Phase 2a clinical trial data at the Alzheimer’s Association International Conference. Lomecel-B™ showed improvements in cognitive function, quality of life, and brain volume in mild Alzheimer’s Disease patients. MRI biomarker results also demonstrated a 49% reduction in brain volume loss. The study met its key objectives, supporting the favorable benefit/risk profile and efficacy profile of Lomecel-B™. The FDA has granted Lomecel-B™ RMAT and Fast Track designations for the treatment of mild Alzheimer’s Disease, highlighting its potential therapeutic impact. These findings offer hope for treating Alzheimer’s Disease effectively and safely in the future.



Read more at GlobeNewswire: Longeveron® Presents Study Results from CLEAR MIND Phase 2a